Windtree Therapeutics, Inc. Inventory

Inventory of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Inventory growth rates and interactive chart. Inventory is the term for the goods available for sale and raw materials used to produce goods available for sale. Inventory represents one of the most important assets of a business because the turnover of inventory represents one of the primary sources of revenue generation and subsequent earnings for the company's shareholders.


Highlights and Quick Summary

  • Inventory for the quarter ending December 30, 2014 was $27 Thousand (a -93.71% decrease compared to previous quarter)
  • Year-over-year quarterly Inventory decreased by -84.39%
  • Annual Inventory for 2014 was $27 Thousand (a -75.89% decrease from previous year)
  • Annual Inventory for 2013 was $112 Thousand (a -42.56% decrease from previous year)
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Inventory of Windtree Therapeutics, Inc.

Most recent Inventoryof WINT including historical data for past 10 years.

Interactive Chart of Inventory of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Inventory for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2014 $0.03 $0.43 $0.44 $0.17 $0.03
2013 $0.11 $0.12 $0.04 $0.11
2012 $0.2 $0.13 $0.11 $0.2

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.